Review: taking Coumadin and Nasonex together


Summary

Drug interactions are reported among people who take Coumadin and Nasonex together. This review analyzes the effectiveness and drug interactions between Coumadin and Nasonex. It is created by eHealthMe based on reports of 809 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Coumadin

Coumadin has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. (latest outcomes from Coumadin 101,806 users)

Nasonex

Nasonex has active ingredients of mometasone furoate monohydrate. It is often used in hypersensitivity. (latest outcomes from Nasonex 18,053 users)

On Sep, 18, 2016

809 people who take Coumadin, Nasonex are studied.


Number of reports submitted per year:

Coumadin and Nasonex drug interactions.

Drug effectiveness over time:

Coumadin:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Nasonex:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Coumadin:
  • female: 50.0% - (2 of 4 people)
  • male: 100.0% - (1 of 1 people)
Nasonex:
  • female: 50.0% - (2 of 4 people)
  • male: 0.0% - (0 of 1 people)

Drug effectiveness by age:

Coumadin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 100.0% - (1 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 66.0% - (2 of 3 people)
Nasonex:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 100.0% - (1 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 33.0% - (1 of 3 people)

Most common drug interactions over time *:

< 1 month:
  • hereditary angioedema
  • pancreatitis
  • transaminases increased
  • urinary tract infection
  • anaemia
  • hepatic enzyme increased
  • angioedema
  • international normalised ratio increased
  • anosmia
  • blindness unilateral
1 - 6 months:
  • abdominal discomfort
  • abdominal distension
  • hepatic failure
  • hepatitis
  • liver function test abnormal
  • nausea
  • necrosis
  • oedema peripheral
  • vomiting
  • anaemia
6 - 12 months:
  • gastrointestinal haemorrhage
  • productive cough
1 - 2 years:
  • diarrhoea
  • febrile neutropenia
  • hepatitis acute
  • keratitis
  • laryngeal oedema
  • pancreatitis acute
  • rash generalised
  • transient ischaemic attack
2 - 5 years:
  • anxiety
  • diarrhoea
  • dyspnoea
  • emotional distress
  • febrile neutropenia
  • hepatitis acute
  • intestinal haemorrhage
  • keratitis
  • laryngeal oedema
  • pain
5 - 10 years:
  • asthenia
  • constipation
  • contusion
  • cough
  • epicondylitis
  • epistaxis
  • headache
  • hepatic enzyme increased
  • injection site pain
  • international normalised ratio decreased
10+ years:
  • aphagia
  • c-reactive protein increased
  • coma
  • general physical health deterioration
  • haematuria
  • haemoglobin decreased
  • haemorrhage
  • hypotonia
  • international normalised ratio increased
  • pyrexia
not specified:
  • dyspnoea
  • fatigue
  • pain
  • anaemia
  • anxiety
  • chest pain
  • back pain
  • nausea
  • cardiac failure congestive
  • pneumonia

Most common drug interactions by gender *:

female:
  • dyspnoea
  • pain
  • anxiety
  • urinary tract infection
  • anaemia
  • nausea
  • headache
  • fatigue
  • vomiting
  • chest pain
male:
  • fatigue
  • chest pain
  • anaemia
  • cardiac failure congestive
  • pain
  • dizziness
  • back pain
  • dyspnoea
  • oedema peripheral
  • pneumonia

Most common drug interactions by age *:

2-9:
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • blood alkaline phosphatase increased
  • chronic obstructive airways disease
  • liver function test abnormal
  • nasopharyngitis
  • respiratory failure
10-19:
  • anxiety
  • deep vein thrombosis
  • headache
  • injury
  • intracranial venous sinus thrombosis
  • pain
20-29:
  • cardiac failure congestive
  • bronchitis
  • cholecystitis
  • influenza like illness
  • insomnia
  • urinary tract infection
  • atrial fibrillation
  • intracardiac thrombus
  • mass
  • multi-organ failure
30-39:
  • colitis
  • congestive cardiomyopathy
  • dehydration
  • depression
  • emphysema
  • hepatic steatosis
  • intracardiac thrombus
  • pericardial effusion
  • renal failure
  • respiratory arrest
40-49:
  • urinary tract infection
  • pneumonia
  • anaemia
  • fatigue
  • pain
  • hereditary angioedema
  • dehydration
  • pancreatitis
  • transaminases increased
  • pleural effusion
50-59:
  • anxiety
  • fall
  • chest pain
  • nausea
  • pain
  • anaemia
  • depression
  • dyspnoea
  • fatigue
  • gastritis
60+:
  • dyspnoea
  • fatigue
  • oedema peripheral
  • dizziness
  • anaemia
  • chest pain
  • atrial fibrillation
  • pain
  • cardiac failure congestive
  • hypotension

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Coumadin and Nasonex?

Can you answer these questions?

More questions for: Coumadin, Nasonex

You may be interested in these reviews

More reviews for: Coumadin, Nasonex

On eHealthMe, Coumadin (warfarin sodium) is often used to treat atrial fibrillation/flutter. Nasonex (mometasone furoate monohydrate) is often used to treat hypersensitivity. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.